Student or educator? Sign up with your school email and get 6 months of Pro free.

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction

Open access

Abstract

Aims: Patients with heart failure and preserved ejection fraction (HFpEF) frequently have difficult-to-control hypertension. We examined the effect of neprilysin inhibition on ‘apparent resistant hypertension’ in patients with HFpEF in the PARAGON-HF trial, which compared the effect of sacubitril–valsartan with valsartan. Methods and results: In this post hoc analysis, patients were categorized according to systolic blood pressure at the end of the valsartan run-in (n = 4795). ‘Apparent resistant hypertension’ was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite treatment with valsartan, a calcium channel blocker, and a diuretic. ‘Apparent mineralocorticoid receptor antagonist (MRA)-resistant’ hypertension was defined as systolic blood pressure ≥140 mmHg (≥135 mmHg if diabetes) despite the above treatments and an MRA. The primary outcome in the PARAGON-HF trial was a composite of total hospitalizations for heart failure and death from cardiovascular causes. We examined clinical endpoints and the safety of sacubitril–valsartan according to the hypertension category. We also examined reductions in blood pressure from the end of valsartan run-in to Weeks 4 and 16 after randomization. Overall, 731 patients (15.2%) had apparent resistant hypertension and 135 (2.8%) had apparent MRA-resistant hypertension. The rate of the primary outcome was higher in patients with apparent resistant hypertension [17.3; 95% confidence interval (CI) 15.6–19.1 per 100 person-years] compared to those with a controlled systolic blood pressure (13.4; 12.7–14.3 per 100 person-years), with an adjusted rate ratio of 1.28 (95% CI 1.05–1.57). The reduction in systolic blood pressure at Weeks 4 and 16, respectively, was greater with sacubitril–valsartan vs. valsartan in patients with apparent resistant hypertension [−4.8 (−7.0 to −2.5) and 3.9 (−6.6 to −1.3) mmHg] and apparent MRA-resistant hypertension [−8.8 (−14.0 to −3.5) and −6.3 (−12.5 to −0.1) mmHg]. The proportion of patients with apparent resistant hypertension achieving a controlled systolic blood pressure by Week 16 was 47.9% in the sacubitril–valsartan group and 34.3% in the valsartan group [adjusted odds ratio (OR) 1.78, 95% CI 1.30–2.43]. In patients with apparent MRA-resistant hypertension, the respective proportions were 43.6% vs. 28.4% (adjusted OR 2.63, 95% CI 1.18–5.89). Conclusion: Sacubitril–valsartan may be useful in treating apparent resistant hypertension in patients with HFpEF, even in those who continue to have an elevated blood pressure despite treatment with at least four antihypertensive drug classes, including an MRA. Clinical trial registration: PARAGON-HF: ClinicalTrials.gov Identifier NCT01920711.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurheartj/ehab499

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Figures

Graphical abstract Almost one in six patients with heart failure and preserved ejection fraction had apparent resistant hypertension in PARAGON-HF and this was associated with worse clinical outcomes; neprilysin inhibition reduced systolic blood pressure significantly in these patients.
Graphical abstract Almost one in six patients with heart failure and preserved ejection fraction had apparent resistant hypertension in PARAGON-HF and this was associated with worse clinical outcomes; neprilysin inhibition reduced systolic blood pressure significantly in these patients.CC BY-NC · PubMed Central
Figure 1 Hazard and survival curves according to hypertension category. (A) Primary outcome. (B) Total heart failure hospitalizations. (C) Cardiovascular death, total heart failure hospitalizations, strokes, and myocardial infarctions. (D) Cardiovascular death. BP, blood pressure; CV, cardiovascular; HF, heart failure; MI, myocardial infarction.
Figure 1 Hazard and survival curves according to hypertension category. (A) Primary outcome. (B) Total heart failure hospitalizations. (C) Cardiovascular death, total heart failure hospitalizations, strokes, and myocardial infarctions. (D) Cardiovascular death. BP, blood pressure; CV, cardiovascular; HF, heart failure; MI, myocardial infarction.CC BY-NC · PubMed Central
Figure 2 Change in systolic blood pressure in patients with controlled blood pressure, ‘non-resistant’, ‘apparent resistant’, and ‘apparent mineralocorticoid receptor antagonist-resistant’ hypertension. Week −2 = end of the open run-in period of treatment with valsartan 80 mg twice daily and Week 0 = end of the open run-in period of treatment with sacubitril–valsartan 49/51 mg, Thereafter, patients randomized to double-blind treatment with valsartan 160 mg twice daily or sacubitril–valsartan 97/103 mg twice daily. Models include systolic blood pressure at the end of the valsartan run-in, age, sex, body mass index, cigarette smoking, and region, as well as systolic blood pressure at all other time points up to Week 16 and an interaction term between treatment and time. MRA, mineralocorticoid receptor antagonist.
Figure 2 Change in systolic blood pressure in patients with controlled blood pressure, ‘non-resistant’, ‘apparent resistant’, and ‘apparent mineralocorticoid receptor antagonist-resistant’ hypertension. Week −2 = end of the open run-in period of treatment with valsartan 80 mg twice daily and Week 0 = end of the open run-in period of treatment with sacubitril–valsartan 49/51 mg, Thereafter, patients randomized to double-blind treatment with valsartan 160 mg twice daily or sacubitril–valsartan 97/103 mg twice daily. Models include systolic blood pressure at the end of the valsartan run-in, age, sex, body mass index, cigarette smoking, and region, as well as systolic blood pressure at all other time points up to Week 16 and an interaction term between treatment and time. MRA, mineralocorticoid receptor antagonist.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Cited by

See all 156

Metadata

Authors
Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., Rouleau, J. L., Saraiva, J. F. K., Senni, M., Vardeny, O., Wijkman, M. O., Yilmaz, M. B., Saito, Y., Zile, M. R., Solomon, S. D., & McMurray, J. J. V.
Affiliations
  • British Heart Foundation (GB)
  • University of Minnesota (US)
  • Charité – Universitätsmedizin Berlin (DE)
  • University Medical Center Groningen (NL)
  • Novartis (United States) (US)
  • Ziekenhuis Groep Twente (NL)
  • Karolinska University Hospital (SE)
  • Maria Cecilia Hospital (IT)
  • Brigham and Women's Hospital (US)
  • Montreal Heart Institute (CA)
  • Disciplina de Cardiologia Faculdade de Medicina, Pontifícia Universidade Católica de Campinas , Sao Paulo, Brazil
  • Ospedale Papa Giovanni XXIII (IT)
  • Linköping University (SE)
  • Department of Cardiology, Faculty of Medicine, Dokuz Eylul University, Izmir, Turkey
  • Nara Medical University (JP)
  • Medical University of South Carolina (US)
Corresponding author
McMurray, John J V
Venue
European Heart Journal
Published
2021-08-15
Volume
42
Issue
36
Pages
3741-3752
ISSN
  • 0195-668X (ISSN-L)
  • 1522-9645
OpenAlex
W3193922103
Cited by
156
References
42
Citations by year
2026: 10 · 2025: 34 · 2024: 39 · 2023: 37 · 2022: 25 · 2021: 10
FWCI
18.59
Type
journal article
Language
en
Open access
Locations
  • European Heart Journal (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, other-oa)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, cc-by-sa)
  • KTH Publication Database DiVA (KTH Royal Institute of Technology) (submittedVersion, other-oa)
  • BOA (University of Milano-Bicocca) (submittedVersion, cc-by-nc)
  • University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, cc-by-nc)
Funders
  • British Heart Foundation Clinical Research Training Fellowship (FS/18/14/33330)
  • British Heart Foundation Centre of Research Excellence (RE/18/6/34217)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Blood Pressure and Hypertension Studies
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart rate and cardiovascular health
Keywords
sacubitril/valsartan, valsartan, heart failure with preserved ejection fraction, resistant hypertension, neprilysin inhibition, blood pressure reduction, PARAGON-HF trial, heart failure hospitalization, cardiovascular mortality, drug safety, diabetes mellitus, systolic blood pressure control
MeSH terms
Valsartan, Aminobutyrates, Biphenyl Compounds, Double-Blind Method, Drug Combinations, Heart Failure, Humans, Hypertension, Stroke Volume, Tetrazoles, Neprilysin, Treatment Outcome, Angiotensin Receptor Antagonists

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. https://app.cochat.ai/papers/10.1093/eurheartj/ehab499
The paper
Jackson, A. M., Jhund, P. S., Anand, I. S., Düngen, H.-D., Lam, C. S. P., Lefkowitz, M. P., Linssen, G., Lund, L. H., Maggioni, A. P., Pfeffer, M. A., Rouleau, J. L., Saraiva, J. F. K., Senni, M., Vardeny, O., Wijkman, M. O., Yilmaz, M. B., Saito, Y., Zile, M. R., Solomon, S. D., & McMurray, J. J. V. (2021). Sacubitril–valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction. European Heart Journal. https://doi.org/10.1093/eurheartj/ehab499

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.